Targeting Cellular Senescence Enhances Post-Burn Wound Healing in Aged Mice.
Key claim: In aged mice, Dasatinib plus Quercetin senolytic treatment cleared burn-wound senescent cells and improved macroscopic healing, myofibroblast markers, and type I collagen versus untreated aged burns.
Abstract
-Despite advancements in burn care, older burn patients continue to experience disproportionately high mortality rates. Impaired wound healing is a major prognostic indicator of burn patient survival, yet the mechanisms underlying delayed repair in older adults remain poorly understood. Cellular senescence, a hallmark of aging, contributes to tissue dysfunction and impaired regeneration, making it a potential mediator of age-associated deficits in burn wound healing. Here, we investigated the role of cellular senescence in postburn wound repair using a validated adult and aged murine full-thickness scald burn model and evaluated whether senolytic treatment with Dasatinib and Quercetin improves healing outcomes in aged mice. Thermal injury increased senescence-associated features in burn wounds, including senescence-associated beta-galactosidase-positive skin cells, and was associated with reduced myofibroblast-associated marker expression, increased extracellular matrix-degrading components, and delayed wound healing in aged mice. In contrast, senolytic treatment in aged burn mice reduced cellular senescence, demonstrated by a 4.4-fold decrease in senescence-associated beta-galactosidase-positive skin cells to baseline levels, increased alpha smooth muscle actin and type I collagen expression, and improved macroscopic burn wound healing. Together, these findings suggest that cellular senescence is associated with impaired skin repair after burn injury and that senescence-targeting therapies may represent a potential strategy to improve wound healing outcomes in older burn patients.
Why this matters
Age-impaired wound healing is a clinically visible failure mode of tissue repair, and this study pins part of that failure on accumulated senescent cells at the burn-wound site rather than on intrinsic fibroblast exhaustion alone. It extends the D+Q preclinical roster — already covering liver, kidney, cardiac, ALS, and vascular contexts — into an acute aged-injury model where the readouts (myofibroblast markers, collagen I, macroscopic closure) map directly onto surgical and burn-care endpoints, even though no human burn-wound senolytic trial exists.